IXICO's analysis technology is being used by a US biopharma for a phase II trial of a new treatment for Huntington’s disease and by a different company for a Phase II/III clinical trial contract in Alzheimer's disease; the scope of both contracts has been extended
Original Article: IXICO sees contracts' value increased by around £500,000